Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Lilly in a statement Friday said it will ask the CHMP to reexamine its opinion. Given the drug's approval by regulators in other countries, "Lilly remains confident in the safety and effectiveness of ...

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...